"MTx today announces a collaboration with Northway to establish fast-track cGMP manufacturing for its lead antibody candidate for the treatment of COVID-19," it said a press release.
"Under the terms of the manufacturing agreement, Northway will develop the cell line and the manufacturing process, and will further produce cGMP batches of MTx's antibody for clinical studies."
The antibody developed by MTx and manufactured by Northway Biotechpharma is expected to reach the market in 2021, if clinical trial results are positive, the Lithuanian company said.
Northway Biotechpharma, which is indirectly controlled by Vladas Bumelis, its board chairman, has posted a net profit of almost 16 million euros for 2019. Annual revenue grew to 37.703 million euros.